{{Rsnum
|rsid=617219
|Gene=BHMT
|Chromosome=5
|position=79133771
|Orientation=plus
|GMAF=0.3558
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 46.9 | 43.4 | 9.7
| HCB | 31.4 | 56.9 | 11.7
| JPT | 44.2 | 38.9 | 16.8
| YRI | 55.8 | 38.8 | 5.4
| ASW | 49.1 | 36.8 | 14.0
| CHB | 31.4 | 56.9 | 11.7
| CHD | 37.6 | 45.9 | 16.5
| GIH | 29.7 | 43.6 | 26.7
| LWK | 67.3 | 26.4 | 6.4
| MEX | 22.4 | 60.3 | 17.2
| MKK | 62.3 | 34.4 | 3.2
| TSI | 37.3 | 52.0 | 10.8
| HapMapRevision=28
}}[[Yasko Methylation]] The product the BHMT gene is central to the ‘short cut’ through the methylation cycle, again helping to convert homocysteine to methionine. The activity of this gene product can be affected by stress, by cortisol levels and may play a role in ADD/ADHD by affecting norepinephrine levels.
Yasko believes that believes BHMT-02 and BHMT-04 play a role in the gut environment. Yasko also believes that BHMT-08 is related to the impact that psychological stress has on a patient's attention levels.

{{PMID Auto
|PMID=19493349
|Title=118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}